Streetbeat News

Products Services

GOOGL

Samsung's upcoming Galaxy Z Flip 5 foldable smartphone has been leaked, revealing a larger 3.4-inch outer display and dual camera setup. Samsung has partnered with Google to offer customized Google applications on the device.

Portfolio Pulse from Rounak Jain

June 16, 2023 | 9:44 am

TSLA

Tesla's stock rally paused after a 13-session winning streak, but an analyst predicts further upside due to Q2 deliveries and Cybertruck launch. The analyst expects a record Q2 volume of 450,000 units, up 76% YoY, and more analysts to revise their price targets upward.

Portfolio Pulse from Shanthi Rexaline

June 16, 2023 | 9:21 am

FXI

TSLA

Tesla is offering an 8,000 yuan insurance subsidy to some Model 3 buyers in China from June 16 to June 30, according to a Reuters report.

Portfolio Pulse from Charles Gross

June 16, 2023 | 9:11 am

NEO

Neogenomics announced that its RaDaR assay, a personalized liquid biopsy for minimal/molecular residual disease and recurrence detection, has obtained its first pan-cancer commercial coverage by Blue Shield of California.

Portfolio Pulse from Benzinga Newsdesk

June 16, 2023 | 8:46 am

META

WhatsApp, owned by Meta Platforms Inc. (NASDAQ:META), is reportedly working on multi-account support to compete with rival Telegram. The latest WhatsApp Business beta for Android contains references to this functionality, allowing users to log into multiple accounts on the same phone.

Portfolio Pulse from Ananya Gairola

June 16, 2023 | 8:44 am

RETA

The FDA has accepted Reata Pharmaceuticals' filing of the Prior Approval Supplement (PAS) to update the drug substance specification for Skyclarys (Omaveloxolone). The PAS is under expedited Priority Review with a target action date of mid-August 2023.

Portfolio Pulse from Benzinga Newsdesk

June 16, 2023 | 8:44 am

BMY

The FDA has approved Bristol Myers Squibb's supplemental new drug application to add data from the Phase 3 VALOR-HCM study to the U.S. prescribing information for Camzyos (Mavacamten). This follows last year's FDA approval of Camzyos based on results from the Phase 3 EXPLORER-HCM trial.

Portfolio Pulse from Benzinga Newsdesk

June 16, 2023 | 8:41 am

HCM

TAK

Hutchmed and Takeda announced positive results from their Phase 3 FRESCO-2 study of Fruquintinib in patients with previously treated metastatic colorectal cancer, published in The Lancet. The study showed a 34% reduction in the risk of death.

Portfolio Pulse from Benzinga Newsdesk

June 16, 2023 | 8:37 am

BTTX

Better Therapeutics (BTTX) will present a poster at the EASL Congress 2023 in Austria, showcasing findings from a feasibility study on non-alcohol related fatty liver disease.

Portfolio Pulse from Benzinga Newsdesk

June 16, 2023 | 8:35 am

IPHA

Innate Pharma announced interim efficacy results from the TELLOMAK Phase 2 study in advanced mycosis fungoides, confirming clinical activity and a favorable safety profile of Lacutamab with an updated ORR of 42.9%.

Portfolio Pulse from Benzinga Newsdesk

June 16, 2023 | 8:32 am